MA34449B1 - Formulation de poudre seche comprenant un inhibiteur de phosphodiesterase - Google Patents
Formulation de poudre seche comprenant un inhibiteur de phosphodiesteraseInfo
- Publication number
- MA34449B1 MA34449B1 MA35635A MA35635A MA34449B1 MA 34449 B1 MA34449 B1 MA 34449B1 MA 35635 A MA35635 A MA 35635A MA 35635 A MA35635 A MA 35635A MA 34449 B1 MA34449 B1 MA 34449B1
- Authority
- MA
- Morocco
- Prior art keywords
- dry powder
- powder formulation
- phosphodiesterase inhibitor
- relates
- phosphodiesterase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
L'invention concerne une formulation pharmaceutique sous la forme d'une poudre sèche pouvant être inhalée, comprenant des particules d'un inhibiteur de la phosphodiestérase-4 en tant que principe actif. L'invention concerne également son procédé de préparation et son utilisation dans la prévention et/ou le traitement d'une maladie respiratoire, telle que l'asthme et la maladie pulmonaire obstructive chronique (COPD).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10171748 | 2010-08-03 | ||
| PCT/EP2011/062872 WO2012016889A2 (fr) | 2010-08-03 | 2011-07-27 | Formulation de poudre sèche comprenant un inhibiteur de phosphodiestérase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA34449B1 true MA34449B1 (fr) | 2013-08-01 |
Family
ID=43262631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA35635A MA34449B1 (fr) | 2010-08-03 | 2011-07-27 | Formulation de poudre seche comprenant un inhibiteur de phosphodiesterase |
Country Status (39)
| Country | Link |
|---|---|
| US (2) | US9132121B2 (fr) |
| EP (2) | EP3246016B1 (fr) |
| JP (1) | JP6004233B2 (fr) |
| KR (1) | KR101805958B1 (fr) |
| CN (2) | CN103052379A (fr) |
| AR (1) | AR082443A1 (fr) |
| AU (1) | AU2011287711B2 (fr) |
| BR (1) | BR112013002506A2 (fr) |
| CA (1) | CA2807256C (fr) |
| CL (1) | CL2013000293A1 (fr) |
| CO (1) | CO6690744A2 (fr) |
| CY (1) | CY1120605T1 (fr) |
| DK (2) | DK2600830T3 (fr) |
| EA (2) | EA027692B1 (fr) |
| ES (2) | ES3033142T3 (fr) |
| FI (1) | FI3246016T3 (fr) |
| GE (1) | GEP20156343B (fr) |
| HR (2) | HRP20180717T1 (fr) |
| HU (2) | HUE037620T2 (fr) |
| IL (1) | IL224517B (fr) |
| LT (2) | LT2600830T (fr) |
| MA (1) | MA34449B1 (fr) |
| ME (1) | ME03022B (fr) |
| MX (1) | MX346424B (fr) |
| MY (1) | MY179703A (fr) |
| NO (1) | NO2600830T3 (fr) |
| NZ (1) | NZ606548A (fr) |
| PE (2) | PE20130601A1 (fr) |
| PH (1) | PH12013500235A1 (fr) |
| PL (2) | PL2600830T3 (fr) |
| PT (2) | PT2600830T (fr) |
| RS (2) | RS57061B1 (fr) |
| SG (1) | SG187258A1 (fr) |
| SI (2) | SI3246016T1 (fr) |
| SM (1) | SMT202500256T1 (fr) |
| TR (1) | TR201807012T4 (fr) |
| UA (1) | UA112296C2 (fr) |
| WO (1) | WO2012016889A2 (fr) |
| ZA (1) | ZA201300870B (fr) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8506934B2 (en) | 2005-04-29 | 2013-08-13 | Robert I. Henkin | Methods for detection of biological substances |
| WO2008095136A2 (fr) | 2007-01-31 | 2008-08-07 | Henkin Robert I | Procédés de détection de substances biologiques |
| EP2022783A1 (fr) | 2007-08-08 | 2009-02-11 | CHIESI FARMACEUTICI S.p.A. | Dérivés d'alcools 1-phényl-2-pyridinylalkyliques en tant qu'inhibiteurs de la phosphodiestérase |
| US8580801B2 (en) | 2008-07-23 | 2013-11-12 | Robert I. Henkin | Phosphodiesterase inhibitor treatment |
| EP2216327A1 (fr) * | 2009-02-06 | 2010-08-11 | CHIESI FARMACEUTICI S.p.A. | Benzoate de (1-Phenyl-2-Pyridin-4-yl)ethyle en tant qu'inhibiteurs de phosphodiestérase |
| RU2578975C2 (ru) | 2010-08-03 | 2016-03-27 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Фармацевтический препарат, содержащий ингибитор фосфодиэстеразы |
| AR086676A1 (es) | 2011-06-06 | 2014-01-15 | Chiesi Farma Spa | Derivados de alcoholes 1-fenil-2-piridinil alquilicos como inhibidores de fosfodiesterasa |
| WO2014072937A1 (fr) | 2012-11-08 | 2014-05-15 | Rhizen Pharmaceuticals Sa | Compositions pharmaceutiques contenant un inhibiteur de pde4 et un inhibiteur de pi3 kinase delta ou un double inhibiteur de pi3 kinase delta et gamma |
| ES2744542T3 (es) * | 2013-03-15 | 2020-02-25 | Robert I Henkin | Inhibidores de fosfodiesterasa para tratar trastornos gustativos y olfativos |
| US9427376B2 (en) * | 2013-10-10 | 2016-08-30 | Chiesi Farmaceutici S.P.A. | Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient |
| HRP20240783T1 (hr) * | 2013-10-22 | 2024-09-27 | Chiesi Farmaceutici S.P.A. | Postupak priprave inhibitora pde4 |
| US20160317542A1 (en) | 2013-12-09 | 2016-11-03 | Respira Therapeutics, Inc. | Pde5 inhibitor powder formulations and methods relating thereto |
| GB201321717D0 (en) * | 2013-12-09 | 2014-01-22 | Pharmachemie Bv | Inhalable Medicaments |
| CN104800192A (zh) * | 2014-01-27 | 2015-07-29 | 成都英诺新科技有限公司 | 一种罗氟司特吸入粉雾剂及制备方法 |
| US10598672B2 (en) | 2014-02-18 | 2020-03-24 | Cyrano Therapeutics, Inc. | Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell |
| EA201692456A1 (ru) * | 2014-07-09 | 2017-08-31 | Арвен Иладж Санайи Ве Тиджарет А.Ш. | Способ получения составов для ингаляции |
| WO2017089347A1 (fr) | 2015-11-25 | 2017-06-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Procédés et compositions pharmaceutiques pour le traitement de mélanomes résistant aux inhibiteurs de braf |
| US10583085B2 (en) * | 2017-05-17 | 2020-03-10 | Chiesi Farmaceutici S.P.A. | Carrier particles for dry powder formulations for inhalation |
| JP7606530B2 (ja) | 2020-03-24 | 2024-12-25 | シラノ セラピューティクス， インコーポレイテッド | コロナウイルス感染症による化学感覚機能障害の治療 |
| US20250058063A1 (en) | 2021-12-21 | 2025-02-20 | Chiesi Farmaceutici S.P.A. | Dry powder formulations filled in an inhaler with improved resistance to humidity |
| IL316500A (en) | 2022-04-27 | 2024-12-01 | Chiesi Farm Spa | Crystal form of a pde4 inhibitor |
| WO2024027901A1 (fr) | 2022-08-02 | 2024-02-08 | Chiesi Farmaceutici S.P.A. | Biomarqueur prédictif de réponse clinique à un inhibiteur de pde4 |
| CN119923251A (zh) * | 2022-09-22 | 2025-05-02 | 奇斯药制品公司 | 用于施用磷酸二酯酶-4抑制剂的胶囊吸入器 |
| EP4590273A1 (fr) * | 2022-09-22 | 2025-07-30 | Chiesi Farmaceutici S.p.A. | Inhalateur à capsule pour l'administration d'un inhibiteur de phosphodiestérase-4 |
| KR20250069948A (ko) * | 2022-09-22 | 2025-05-20 | 키에시 파르마슈티시 엣스. 피. 에이. | 포스포다이에스테라제-4 억제제의 투여를 위한 캡슐 흡입기 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19841248A1 (de) | 1997-09-12 | 1999-04-29 | Fraunhofer Ges Forschung | Demonstrationseinrichtung in Form eines Lebewesens |
| EP1015895B1 (fr) | 1997-09-16 | 2001-07-11 | Trench Switzerland AG | Diviseur de tension |
| ATE363892T1 (de) | 1999-03-05 | 2007-06-15 | Chiesi Farma Spa | Verbesserte pulverformulierungen zur inhalation |
| PE20011227A1 (es) | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
| JP5698423B2 (ja) | 2000-06-27 | 2015-04-08 | ベクトゥラ・リミテッド | 医薬組成物で使用するための粒子の製造法 |
| US20100129363A1 (en) * | 2002-05-17 | 2010-05-27 | Zeldis Jerome B | Methods and compositions using pde4 inhibitors for the treatment and management of cancers |
| DE60239639D1 (de) | 2002-07-31 | 2011-05-12 | Chiesi Farma Spa | Pulverinhalator |
| DE10255387A1 (de) * | 2002-11-28 | 2004-06-09 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Tiotropium-haltige Pulverformulierung für die Inhalation |
| GB0326632D0 (en) * | 2003-11-14 | 2003-12-17 | Jagotec Ag | Dry powder formulations |
| ES2257152B1 (es) | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
| BRPI0610877A2 (pt) * | 2005-06-06 | 2010-08-03 | Hoffmann La Roche | compostos, processo para a manufatura dos compostos, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por inibidores de l-cpt1 e utilização dos mesmos |
| GB0613161D0 (en) * | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
| EP2022783A1 (fr) * | 2007-08-08 | 2009-02-11 | CHIESI FARMACEUTICI S.p.A. | Dérivés d'alcools 1-phényl-2-pyridinylalkyliques en tant qu'inhibiteurs de la phosphodiestérase |
| EP2070913A1 (fr) * | 2007-12-14 | 2009-06-17 | CHIESI FARMACEUTICI S.p.A. | Dérivés d'ester en tant qu'inhibiteurs de la phosphodiestérase |
| EP2216327A1 (fr) | 2009-02-06 | 2010-08-11 | CHIESI FARMACEUTICI S.p.A. | Benzoate de (1-Phenyl-2-Pyridin-4-yl)ethyle en tant qu'inhibiteurs de phosphodiestérase |
| RU2578975C2 (ru) | 2010-08-03 | 2016-03-27 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Фармацевтический препарат, содержащий ингибитор фосфодиэстеразы |
| AR086676A1 (es) | 2011-06-06 | 2014-01-15 | Chiesi Farma Spa | Derivados de alcoholes 1-fenil-2-piridinil alquilicos como inhibidores de fosfodiesterasa |
| HRP20240783T1 (hr) | 2013-10-22 | 2024-09-27 | Chiesi Farmaceutici S.P.A. | Postupak priprave inhibitora pde4 |
-
2011
- 2011-07-27 PE PE2013000155A patent/PE20130601A1/es active IP Right Grant
- 2011-07-27 GE GEAP201112988A patent/GEP20156343B/en unknown
- 2011-07-27 PL PL11741172T patent/PL2600830T3/pl unknown
- 2011-07-27 AU AU2011287711A patent/AU2011287711B2/en active Active
- 2011-07-27 RS RS20180394A patent/RS57061B1/sr unknown
- 2011-07-27 LT LTEP11741172.8T patent/LT2600830T/lt unknown
- 2011-07-27 EP EP17176635.5A patent/EP3246016B1/fr active Active
- 2011-07-27 PT PT117411728T patent/PT2600830T/pt unknown
- 2011-07-27 RS RS20250479A patent/RS66876B1/sr unknown
- 2011-07-27 EA EA201690541A patent/EA027692B1/ru unknown
- 2011-07-27 CN CN2011800382903A patent/CN103052379A/zh active Pending
- 2011-07-27 DK DK11741172.8T patent/DK2600830T3/en active
- 2011-07-27 MY MYPI2013000339A patent/MY179703A/en unknown
- 2011-07-27 LT LTEP17176635.5T patent/LT3246016T/lt unknown
- 2011-07-27 SM SM20250256T patent/SMT202500256T1/it unknown
- 2011-07-27 SG SG2013008107A patent/SG187258A1/en unknown
- 2011-07-27 BR BR112013002506A patent/BR112013002506A2/pt not_active Application Discontinuation
- 2011-07-27 ES ES17176635T patent/ES3033142T3/es active Active
- 2011-07-27 NZ NZ606548A patent/NZ606548A/en unknown
- 2011-07-27 CN CN201710259305.8A patent/CN106890165A/zh active Pending
- 2011-07-27 UA UAA201302607A patent/UA112296C2/uk unknown
- 2011-07-27 HR HRP20180717TT patent/HRP20180717T1/hr unknown
- 2011-07-27 TR TR2018/07012T patent/TR201807012T4/tr unknown
- 2011-07-27 HU HUE11741172A patent/HUE037620T2/hu unknown
- 2011-07-27 JP JP2013522202A patent/JP6004233B2/ja active Active
- 2011-07-27 PE PE2017001245A patent/PE20171256A1/es unknown
- 2011-07-27 ES ES11741172.8T patent/ES2664175T3/es active Active
- 2011-07-27 CA CA2807256A patent/CA2807256C/fr active Active
- 2011-07-27 EA EA201390049A patent/EA024922B1/ru unknown
- 2011-07-27 SI SI201132132T patent/SI3246016T1/sl unknown
- 2011-07-27 MA MA35635A patent/MA34449B1/fr unknown
- 2011-07-27 FI FIEP17176635.5T patent/FI3246016T3/fi active
- 2011-07-27 EP EP11741172.8A patent/EP2600830B1/fr active Active
- 2011-07-27 NO NO11741172A patent/NO2600830T3/no unknown
- 2011-07-27 HR HRP20250711TT patent/HRP20250711T1/hr unknown
- 2011-07-27 PH PH1/2013/500235A patent/PH12013500235A1/en unknown
- 2011-07-27 WO PCT/EP2011/062872 patent/WO2012016889A2/fr not_active Ceased
- 2011-07-27 KR KR1020137002872A patent/KR101805958B1/ko active Active
- 2011-07-27 PT PT171766355T patent/PT3246016T/pt unknown
- 2011-07-27 PL PL17176635.5T patent/PL3246016T3/pl unknown
- 2011-07-27 ME MEP-2018-101A patent/ME03022B/fr unknown
- 2011-07-27 HU HUE17176635A patent/HUE071256T2/hu unknown
- 2011-07-27 DK DK17176635.5T patent/DK3246016T3/da active
- 2011-07-27 MX MX2013001172A patent/MX346424B/es active IP Right Grant
- 2011-07-27 SI SI201131448T patent/SI2600830T1/en unknown
- 2011-08-02 AR ARP110102782 patent/AR082443A1/es not_active Application Discontinuation
- 2011-08-02 US US13/195,885 patent/US9132121B2/en active Active
-
2013
- 2013-01-30 CL CL2013000293A patent/CL2013000293A1/es unknown
- 2013-01-31 IL IL224517A patent/IL224517B/en active IP Right Grant
- 2013-02-01 CO CO13019325A patent/CO6690744A2/es unknown
- 2013-02-01 ZA ZA2013/00870A patent/ZA201300870B/en unknown
-
2015
- 2015-08-07 US US14/820,939 patent/US9308200B2/en active Active
-
2018
- 2018-03-09 CY CY181100288T patent/CY1120605T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA34449B1 (fr) | Formulation de poudre seche comprenant un inhibiteur de phosphodiesterase | |
| MA33299B1 (fr) | Nouvelle formulation de naproxène | |
| MA34765B1 (fr) | Antagonistes des récepteurs de l'acide lysophosphatidique et utilisations de ceux-ci | |
| MA38397A1 (fr) | Agglomérats inhalables de particules de support poreuses et médicament micronisé | |
| MA34326B1 (fr) | Formulation de poudre sèche comprenant un médicament antimuscarinique | |
| MA33295B1 (fr) | Nouvelle formulation de diclofénac | |
| BR112012019374A2 (pt) | composição farmacêutica, pellet de liberação prolongada, composição farmacêutica oral, método para tratamento de uma doença neurodegenerativa ou um dano ao sistema nervoso em um indivíduo necessitado do mesmo e método para preparação de uma formulação de liberação prolongada de um agente ativo | |
| MA33488B1 (fr) | Motifs de modification chimique pour des inhibiteurs et mimétiques de miarn | |
| BR112015015477A2 (pt) | derivados de 2,3-di-hidro-isoindol-1-ona e métodos de uso dos mesmos como inibidores de btk | |
| MA33467B1 (fr) | Promédicaments comprenant un conjugué insuline-lieur | |
| MA32230B1 (fr) | Formes cristallines et deux formes solvatées de lactates de 4-amino-5-fluoro -3-[5-(4-méthylpipérazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one | |
| MX344787B (es) | Composiciones que contienen berberina o analogos de la misma para tratar rosacea o trastornos de la piel relacionados con enrojecimiento de la cara. | |
| EP2823819A4 (fr) | Composition pharmaceutique contenant de l'acétate d'acide oléanolïque en tant que principe actif pour la prévention ou le traitement de maladie à médiation par tlr ou il-6 | |
| WO2011151722A3 (fr) | Méthodes et compositions de traitement pharmaceutique par voie orale | |
| MA46268B1 (fr) | Dérivés de 5-[2-(pyridin-2-ylamino)-1 ,3-thiazol-5-yl]-2,3-dihydro-1h-isoindol-1-one et leur utilisation en tant qu'inhibiteurs doubles de phosphatidylinositol 3-kinase delta & gamma | |
| PH12014501545A1 (en) | Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof | |
| EP2886112A4 (fr) | Composition contenant comme principe actif de la s-allyl-l-cystéine et destinée à prévenir ou à traiter des maladies oculaires, et formulation pharmaceutique contenant cette composition | |
| MA34106B1 (fr) | Combinaison de composés organiques | |
| EA201170583A1 (ru) | Новая композиция для лечения эссенциальной тромбоцитемии | |
| MA33705B1 (fr) | Compositions pour l'inhalation comprenant de l'acide de montelukast et un inhibiteur de la pde-4 ou un corticosteroide inhale | |
| JP2011500731A5 (fr) | ||
| WO2013181217A3 (fr) | Nouveaux composés et nouvelles compositions pour le traitement de troubles ou de maladies du contrôle de la respiration | |
| EP2583966A4 (fr) | Dérivé de rgd cyclique marqué par du tricarbonyl-technétium-99m ou -rhénium-188, son procédé de préparation et composition pharmaceutique contenant le dérivé comme principe actif destinée à être utilisée dans le diagnostic ou le traitement de maladies liées à l'angiogenèse | |
| EP2351567A4 (fr) | Composition pharmaceutique et medicament pour la prevention et le traitement de diabetes ou de l'obesite comprenant comme principe actif, un compose qui inhibe l'activation de dipeptidyl peptidase-iv | |
| EP2873419A4 (fr) | Composition pharmaceutique comprenant de l'azathioprine en tant que principe actif pour la prévention ou le traitement de tumeurs du cerveau ou de glioblastomes résistants à témodal |